Kura Oncology (NASDAQ:KURA) Insider Teresa Brophy Bair Sells 8,805 Shares

Key Points

• Insider Sale: Kura Oncology insider Teresa Brophy Bair sold 8,805 shares at an average price of $8.94, totaling approximately $78,717, resulting in a 5.61% decrease in her ownership.
• Stock Performance: Kura Oncology's shares are currently trading down 0.9% at $8.97, with a market capitalization of $778.60 million and a P/E ratio of -3.97.
• Earnings Report: The company reported a loss of $0.75 per share for the last quarter, missing analyst estimates, and generated revenue of $15.29 million, significantly below the expected $64.95 million.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Teresa Brophy Bair sold 8,805 shares of the company's stock in a transaction on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $78,716.70. Following the sale, the insider owned 148,043 shares of the company's stock, valued at $1,323,504.42. This trade represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kura Oncology Stock Down 0.9%

NASDAQ:KURA traded down $0.08 during mid-day trading on Monday, hitting $8.97. 2,168,205 shares of the company's stock traded hands, compared to its average volume of 1,613,537. The company has a fifty day moving average of $7.39 and a 200 day moving average of $6.65. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The company has a market capitalization of $778.60 million, a P/E ratio of -3.97 and a beta of 0.19. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $19.93.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. On average, analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently modified their holdings of the company. BVF Inc. IL grew its stake in shares of Kura Oncology by 202.0% in the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock valued at $51,177,000 after buying an additional 5,186,660 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Kura Oncology by 13.3% in the first quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock valued at $43,375,000 after buying an additional 772,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Kura Oncology by 2.7% in the first quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock valued at $32,658,000 after buying an additional 129,337 shares in the last quarter. EcoR1 Capital LLC grew its stake in shares of Kura Oncology by 59.1% in the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company's stock valued at $24,234,000 after buying an additional 1,559,702 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Kura Oncology by 11.7% in the second quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company's stock valued at $11,623,000 after buying an additional 211,470 shares in the last quarter.

Analyst Ratings Changes

Several analysts recently commented on KURA shares. Wall Street Zen raised Kura Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research note on Thursday, June 26th. JMP Securities lowered their price target on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research note on Monday, August 11th. Guggenheim initiated coverage on Kura Oncology in a research note on Thursday, September 4th. They issued a "neutral" rating on the stock. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $24.10.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.